Carteolol Ophthalmic Solution

Mechanism :

Carteolol HCl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Carteolol reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by glaucoma. The exact mechanism of the ocular hypotensive effect of beta-blockers has not been demonstrated.

Indication :

• Chronic open-angle glaucoma
• Intraocular hypertension

Contraindications :

Contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease; sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product.

Dosing :

Adverse Effect :

Transient eye irritation, burning, tearing, conjunctival hyperemia and edema, bradycardia, hypotension, cardiac arrhythmia, headache, dizziness, insomnia, sinusitis, taste perversion.

Interaction :

Beta-adrenergic blocking agent: Should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

Hepatic Dose :